Celsion Corp (CLSN) 2.42 $CLSN
Celsion's Prospects For A Significant Upside Just Got A Lot Better
Clinically Sound Investor - at Seeking Alpha - Thu Nov 20, 11:12AM CST
CLSN: 2.42 (unch)
Celsion net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:18AM CST
CLSN: 2.42 (unch)
Celsion's (CLSN) CEO Michael Tardugno on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:54PM CST
CLSN: 2.42 (unch)
Celsion (CLSN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 11, 3:25PM CST
CLSN: 2.42 (unch)
Celsion misses by $0.03, revenue in-line
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:58AM CST
CLSN: 2.42 (unch)
Celsion Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 11, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the third quarter ended September 30, 2014. The Company also provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas(TM) and TheraSilence(TM), in immunotherapy and RNA delivery.
CLSN: 2.42 (unch)
Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe
PR Newswire - Wed Nov 05, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Phase III OPTIMA Study was approved via Europe's centralized Voluntary Harmonization Procedure (VHP). The approval allows Celsion to conduct the OPTIMA Study, its Phase III trial of ThermoDox® in primary liver cancer, also known as hepatocellular carcinoma (HCC), in Europe. In addition to Italy, the OPTIMA Study will now include sites in Spain and Germany. The OPTIMA Study is the Company's global pivotal, double-blind, placebo-controlled trial, evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat patients with non-resectable HCC lesions. HCC is the largest unmet medical need remaining in oncology with annual incidence over 750,000 and non-resectable RFA candidates representing some 30% of the newly diagnosed patients. The OPTIMA Study is actively recruiting and enrolling patients at sites in the United States, Hong Kong, South Korea, Malaysia and Thailand. Additional clinical sites in Canada, Taiwan, and the Philippines are expected to begin recruitment before the end of the year with China FDA (CFDA) regulatory approval to follow in early 2015.
CLSN: 2.42 (unch)
Celsion reports November 11
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:50AM CST
CLSN: 2.42 (unch)
Celsion Corporation to Hold Third Quarter 2014 Financial Results Conference Call on Tuesday, November 11, 2014
PR Newswire - Tue Nov 04, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its third quarter 2014 financial results at 4:30 p.m. ET on Tuesday, November 11, 2014. To participate in the call, interested parties may dial 1-888-430-8709 (Toll-Free/North America) or 1-719-457-1512 (International/Toll) and ask for the Celsion Corporation Third Quarter 2014 Conference Call (Conference Code: 3981708) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
CLSN: 2.42 (unch)
Celsion Presents Preclinical Data for its TheraSilence(TM) Platform at the miRNA World Conference Workshop on miRNA Delivery
PR Newswire - Wed Oct 29, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced the presentation of data related to TheraSilence(TM), the Company's lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data was presented by Dr. Khursheed Anwer, Celsion's Executive Vice President and Chief Scientific Officer, during a panel presentation, and highlighted formulation characteristics of the TheraSilence delivery platform, preclinical proof-of concept data and data supportive of GEN-2 (formerly referred to as EGEN-002), Celsion's RNA interference (RNAi) therapeutic for the treatment of lung cancer. Celsion acquired the TheraSilence platform and GEN-2 through its acquisition of EGEN, Inc. in June 2014.
CLSN: 2.42 (unch)
Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors
PR Newswire - Tue Oct 07, 4:00PM CDT
Celsion Corporation (NASDAQ: CLSN) announced that the Board of Directors has appointed Michael H. Tardugno, the Company's President and CEO, to the additional position of Executive Chairman of the Board. Mr. Tardugno's appointment is consistent with the Board's previously established succession plan and follows the passing of Max E. Link, Ph.D. which was announced earlier today. At the direction of Mr. Tardugno, the Nominating Committee of the Board of Directors has begun the process to identify qualified candidates to fill the vacancy on the Company's Board.
CLSN: 2.42 (unch), ABT: 43.69 (-0.77), BMY: 58.75 (-0.93)
Celsion Announces The Unexpected Passing of Max E. Link, Ph.D., Chairman of the Board
PR Newswire - Tue Oct 07, 3:35PM CDT
Celsion Corporation (NASDAQ: CLSN) is saddened to announce the passing of Max E. Link, Ph.D., a Director and the Chairman of the Board of Directors of the Company. Dr. Link passed away unexpectedly at the age of 74.
CLSN: 2.42 (unch)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Celsion Corp. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Wed Sep 17, 1:18PM CDT
Levi & Korsinsky, LLP is investigating Celsion Corp. (NasdaqCM: CLSN) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
CLSN: 2.42 (unch)
Celsion Announces Highlights from Three Presentations Given at the International Liver Cancer Association 2014 Annual Conference
PR Newswire - Mon Sep 08, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced highlights from three presentations by three of the world's leading liver cancer experts and principal investigators for the Company's pivotal Phase III OPTIMA Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with standardized radiofrequency ablation (sRFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). The symposium, highly attended by physicians committed to HCC research, was conducted at the International Liver Cancer Association (ILCA) 7th Annual Conference from September 5 - 7, 2014 in Kyoto, Japan.
CLSN: 2.42 (unch)
Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on ThermoDox® in Recurrent Chest Wall Breast Cancer Published in the International Journal of Hyperthermia
PR Newswire - Thu Sep 04, 8:05AM CDT
September 4, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that data from two Phase I studies on ThermoDox® in recurrent chest wall breast cancer were published in the International Journal of Hyperthermia. The article, titled "Two phase 1 dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer," appears in the August 2014 issue (Volume 30, Number 5) and can be accessed here.
CLSN: 2.42 (unch)
Celsion Announces Enrollment of First Patient in Global Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
PR Newswire - Tue Sep 02, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer, also known as hepatocellular carcinoma (HCC). ThermoDox® is Celsion's proprietary, heat-activated, liposomal encapsulation of doxorubicin.
CLSN: 2.42 (unch)
Celsion to Present at the Rodman & Renshaw 16th Annual Healthcare Conference
PR Newswire - Thu Aug 28, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that Michael H. Tardugno, Celsion's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16th Annual Healthcare Conference on Tuesday, September 9,, 2014 at 10:50 a.m. Eastern Time. The conference is being held at The New York Palace Hotel in New York City. A copy of the presentation will be available on Celsion's website at investor.celsion.com/events.cfm.
CLSN: 2.42 (unch)
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.42 (unch), NWBO: 4.98 (+0.04), CVM: 0.57 (+0.01), CLDX: 18.03 (-0.16), INCY: 74.65 (-1.27), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), DNDN: 0.13 (-0.02), NLNK: 35.69 (+0.27), PPHM: 1.48 (-0.01), BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Celsion Corporation Reports Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014. The Company also provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas(TM) and TheraSilence(TM), in immunotherapy and RNA delivery.
CLSN: 2.42 (unch)
Celsion Corporation to Hold Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 31, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its second quarter 2014 financial results at 11:00 a.m. EDT on Thursday, August 7, 2014. To participate in the call, interested parties may dial 1-800-533-7954 (Toll-Free/North America) or 1-785-830-1924 (International/Toll) and ask for the Celsion Corporation Second Quarter 2014 Conference Call (Conference Code: 8283269) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
CLSN: 2.42 (unch)
Celsion's Prospects For A Significant Upside Just Got A Lot Better
Clinically Sound Investor - at Seeking Alpha - Thu Nov 20, 11:12AM CST
CLSN: 2.42 (unch)
Celsion net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:18AM CST
CLSN: 2.42 (unch)
Celsion's (CLSN) CEO Michael Tardugno on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:54PM CST
CLSN: 2.42 (unch)
Celsion (CLSN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 11, 3:25PM CST
CLSN: 2.42 (unch)
Celsion misses by $0.03, revenue in-line
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:58AM CST
CLSN: 2.42 (unch)
Celsion Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 11, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the third quarter ended September 30, 2014. The Company also provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas(TM) and TheraSilence(TM), in immunotherapy and RNA delivery.
CLSN: 2.42 (unch)
Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe
PR Newswire - Wed Nov 05, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Phase III OPTIMA Study was approved via Europe's centralized Voluntary Harmonization Procedure (VHP). The approval allows Celsion to conduct the OPTIMA Study, its Phase III trial of ThermoDox® in primary liver cancer, also known as hepatocellular carcinoma (HCC), in Europe. In addition to Italy, the OPTIMA Study will now include sites in Spain and Germany. The OPTIMA Study is the Company's global pivotal, double-blind, placebo-controlled trial, evaluating ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation standardized to 45 minutes (sRFA) versus sRFA alone to treat patients with non-resectable HCC lesions. HCC is the largest unmet medical need remaining in oncology with annual incidence over 750,000 and non-resectable RFA candidates representing some 30% of the newly diagnosed patients. The OPTIMA Study is actively recruiting and enrolling patients at sites in the United States, Hong Kong, South Korea, Malaysia and Thailand. Additional clinical sites in Canada, Taiwan, and the Philippines are expected to begin recruitment before the end of the year with China FDA (CFDA) regulatory approval to follow in early 2015.
CLSN: 2.42 (unch)
Celsion reports November 11
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:50AM CST
CLSN: 2.42 (unch)
Celsion Corporation to Hold Third Quarter 2014 Financial Results Conference Call on Tuesday, November 11, 2014
PR Newswire - Tue Nov 04, 7:00AM CST
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its third quarter 2014 financial results at 4:30 p.m. ET on Tuesday, November 11, 2014. To participate in the call, interested parties may dial 1-888-430-8709 (Toll-Free/North America) or 1-719-457-1512 (International/Toll) and ask for the Celsion Corporation Third Quarter 2014 Conference Call (Conference Code: 3981708) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
CLSN: 2.42 (unch)
Celsion Presents Preclinical Data for its TheraSilence(TM) Platform at the miRNA World Conference Workshop on miRNA Delivery
PR Newswire - Wed Oct 29, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) today announced the presentation of data related to TheraSilence(TM), the Company's lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data was presented by Dr. Khursheed Anwer, Celsion's Executive Vice President and Chief Scientific Officer, during a panel presentation, and highlighted formulation characteristics of the TheraSilence delivery platform, preclinical proof-of concept data and data supportive of GEN-2 (formerly referred to as EGEN-002), Celsion's RNA interference (RNAi) therapeutic for the treatment of lung cancer. Celsion acquired the TheraSilence platform and GEN-2 through its acquisition of EGEN, Inc. in June 2014.
CLSN: 2.42 (unch)
Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors
PR Newswire - Tue Oct 07, 4:00PM CDT
Celsion Corporation (NASDAQ: CLSN) announced that the Board of Directors has appointed Michael H. Tardugno, the Company's President and CEO, to the additional position of Executive Chairman of the Board. Mr. Tardugno's appointment is consistent with the Board's previously established succession plan and follows the passing of Max E. Link, Ph.D. which was announced earlier today. At the direction of Mr. Tardugno, the Nominating Committee of the Board of Directors has begun the process to identify qualified candidates to fill the vacancy on the Company's Board.
CLSN: 2.42 (unch), ABT: 43.69 (-0.77), BMY: 58.75 (-0.93)
Celsion Announces The Unexpected Passing of Max E. Link, Ph.D., Chairman of the Board
PR Newswire - Tue Oct 07, 3:35PM CDT
Celsion Corporation (NASDAQ: CLSN) is saddened to announce the passing of Max E. Link, Ph.D., a Director and the Chairman of the Board of Directors of the Company. Dr. Link passed away unexpectedly at the age of 74.
CLSN: 2.42 (unch)
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Celsion Corp. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Wed Sep 17, 1:18PM CDT
Levi & Korsinsky, LLP is investigating Celsion Corp. (NasdaqCM: CLSN) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
CLSN: 2.42 (unch)
Celsion Announces Highlights from Three Presentations Given at the International Liver Cancer Association 2014 Annual Conference
PR Newswire - Mon Sep 08, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced highlights from three presentations by three of the world's leading liver cancer experts and principal investigators for the Company's pivotal Phase III OPTIMA Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with standardized radiofrequency ablation (sRFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). The symposium, highly attended by physicians committed to HCC research, was conducted at the International Liver Cancer Association (ILCA) 7th Annual Conference from September 5 - 7, 2014 in Kyoto, Japan.
CLSN: 2.42 (unch)
Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on ThermoDox® in Recurrent Chest Wall Breast Cancer Published in the International Journal of Hyperthermia
PR Newswire - Thu Sep 04, 8:05AM CDT
September 4, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that data from two Phase I studies on ThermoDox® in recurrent chest wall breast cancer were published in the International Journal of Hyperthermia. The article, titled "Two phase 1 dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer," appears in the August 2014 issue (Volume 30, Number 5) and can be accessed here.
CLSN: 2.42 (unch)
Celsion Announces Enrollment of First Patient in Global Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
PR Newswire - Tue Sep 02, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer, also known as hepatocellular carcinoma (HCC). ThermoDox® is Celsion's proprietary, heat-activated, liposomal encapsulation of doxorubicin.
CLSN: 2.42 (unch)
Celsion to Present at the Rodman & Renshaw 16th Annual Healthcare Conference
PR Newswire - Thu Aug 28, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that Michael H. Tardugno, Celsion's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16th Annual Healthcare Conference on Tuesday, September 9,, 2014 at 10:50 a.m. Eastern Time. The conference is being held at The New York Palace Hotel in New York City. A copy of the presentation will be available on Celsion's website at investor.celsion.com/events.cfm.
CLSN: 2.42 (unch)
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.42 (unch), NWBO: 4.98 (+0.04), CVM: 0.57 (+0.01), CLDX: 18.03 (-0.16), INCY: 74.65 (-1.27), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), DNDN: 0.13 (-0.02), NLNK: 35.69 (+0.27), PPHM: 1.48 (-0.01), BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Celsion Corporation Reports Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014. The Company also provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas(TM) and TheraSilence(TM), in immunotherapy and RNA delivery.
CLSN: 2.42 (unch)
Celsion Corporation to Hold Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 31, 7:00AM CDT
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its second quarter 2014 financial results at 11:00 a.m. EDT on Thursday, August 7, 2014. To participate in the call, interested parties may dial 1-800-533-7954 (Toll-Free/North America) or 1-785-830-1924 (International/Toll) and ask for the Celsion Corporation Second Quarter 2014 Conference Call (Conference Code: 8283269) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at http://www.celsion.com.
CLSN: 2.42 (unch)
